BLU-945 Chemical Structure oral EGFR mutant inhibitor - Blueprint Medicines, Cambridge, MA

oral EGFR mutant inhibitor

Ph. I/II candidate oncology

>25k compound library screening and opt

J. Med. Chem

Blueprint Medicines, Cambridge, MA

Context. BLU-945 (Blueprint Medicines) is an oral EGFR mutant inhibitor being developed for treatment-resistant non-small-cell lung cancer (NSCLC). Although three generations of EGFR TKIs are available for EGFR-mutant NSCLC,…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.